Anthralin, a relatively old topical medication, has not received much attention in America until recently, in spite of good results from its use in psoriasis and other chronic dermatoses.
The present study involves treatment of 22 resistant psoriatics with a modification of the Ingram regimen, with most patients in the hospital under observation.
Response was characterized by early rapid flattening of plaques and a significant reduction in total time required for clearing when compared to responses of previous conventional therapy. Side effects were seldom significant. Histologic changes during treatment reflected the rapid response to therapy.
A review of the literature on the mechanism of action of anthralin reveals that it may function as a mitotic inhibitor of the epidermis.
Weigand DA, Everett MA. Clearing of Resistant Psoriasis With Anthralin. Arch Dermatol. 1967;96(5):554–559. doi:10.1001/archderm.1967.01610050076013
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.